OPRX
OptimizeRx Corporation
NasdaqCM Healthcare United States
8,72 $US
+1.75% today
-29.79% YTD · -50.68% 1Y
9
Insider transactions
SEC Form 4 · AMF · BaFin — rolling 90 days
15
Hedge funds tracked
Latest available SEC 13F filings
62
/ 100
STRONG

Analysis OptimizeRx Corporation (OPRX) — Kairos Score 62/100

Composite score aggregating 8 smart money dimensions: insiders (SEC/AMF/BaFin), hedge funds, politicians & gurus, price momentum, valuation, analyst consensus, financial health, earnings momentum. The higher the score, the more favorable the institutional signals consensus.

💡 Detailed breakdown (the 8 sub-scores) available in the Premium dashboard.

About OptimizeRx Corporation

OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.

Key info

👔
CEO
Mr. Stephen L. Silvestro
📍
HQ
260 Charles Street, Suite 302, Waltham, MA, 02453, United States
👥
Employees
132
💰
Market cap
161 989 170,00 $US
📊
P/E
35.2
💸
Dividend yield
—

🕴️ Insider activity (90 days)

9 transactions — 0 buys and 0 sales reported by OptimizeRx Corporation executives.

DA
D'Silva Andrew J.
Chief Business Officer · 2026-10-01
Other
DA
D'Silva Andrew J.
Chief Business Officer · 2026-09-01
Other
MB
Merrell Brendan W.
CHIEF OPERATING OFFICER · 2026-08-21
Other

🏦 Hedge Funds

15 institutional funds report a position on OPRX in their latest SEC quarterly filing.

VANGUARD GROUP INC
ROYCE & ASSOCIATES LP
VANGUARD CAPITAL MANAGEMENT LLC
KENNEDY CAPITAL MANAGEMENT LLC
AQR CAPITAL MANAGEMENT LLC

📰 Recent news

15 recent articles on OPRX.

🧠 What makes Kairos Insider

Beyond raw data, we aggregate and score every smart money signal to give you a unique view.

🧠

Kairos Score 0-100

8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.

🎯

Insider Clusters

Detection of clustered purchases or sales by several executives in the same stock.

🏦

13F Hedge Funds

Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.

📈

ETF Rotations

NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.

🔥

Google Trends

Spot marked changes in search interest around the stocks being followed.

📧

Email alerts

Create your watchlist and receive a brief of events affecting your tickers.

Companies in the same sector as OptimizeRx Corporation

Official sources · Public data · SEC EDGAR — Form 4 & 13F · AMF — Executive filings · BaFin — Directors' Dealings · Yahoo Finance · Alpha Vantage

🔓 Unlock the full analysis

This public page only shows a preview. The full analysis of OPRX on the Kairos Insider dashboard includes:

✅ Full Kairos Score (8-axis radar + synthesis)
✅ History of all 9 insider transactions over 90 days
✅ All 15 detected institutional funds
✅ Thematic ETFs (ARK, BUZZ, NANC, GOP, JEPI…)
✅ Hot Stocks Google Trends
✅ Available history: AUM + rotations
✅ Fundamentals (P/E, PEG, EV/EBITDA, ROE…)
✅ Financial health (Altman Z, Piotroski F)
✅ Sector peers + recent earnings
See full analysis →
Analyze other tickers for free →

Free signup · Pro €19/month or €190/year